"Roche Continents" at the Salzburg Festival celebrates its five-year anniversary

RocheRoche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 different nationalities will come together in Salzburg to discuss creativity in the arts and science and uncover common ground in what at first glance appear to be very different disciplines.

The study week, which took place for the first time in 2007, encourages students to share in discovering concepts of creativity and innovation in the arts, music and science. The concert series "Continents" at the Salzburg Festival is an integral part of the program and provides the students with an opportunity to encounter the work of modern composers, while various workshops allow the participants to exchange ideas and experiences.

Franz B. Humer, Chairman of the Board of Roche, said: "A company that lives from research and innovation must regularly overcome conventional barriers of thought. This ideal is at the heart of the offer that Roche Continents makes to young people of different academic backgrounds. I very much appreciate that this project is taking place for the fifth year in cooperation with the Salzburg Festival."

Helga Rabl-Stadler, President of the Salzburg Festival, added: "The arts and science are connected by the human ambition to understand and experience. The Salzburg Festival has always offered a platform for this. We therefore welcome that Roche supports this tradition both financially and morally and allows young people to experience it."

About Roche Continents
Roche has a long tradition of supporting artistic and cultural projects. Roche Continents is a project that has grown from Roche's partnership with the Salzburg Festival, where the company sponsors "Continents", a new series of concerts featuring the works of contemporary composers. Roche Continents is aimed at students and young scientists aged between 20 and 29 from across Europe. It enables them to experience performances of contemporary music and to discover the common ground of creativity in the arts and science. In Salzburg participants meet up to 100 other students from all parts of Europe to explore topics from the worlds of art and science. Together they attend performances of works by outstanding modern composers at the Salzburg Festival.

About the Salzburg Festival
This year the Salzburg Festival celebrates its ninetieth anniversary. In the midst of the First World War, founding fathers Hugo von Hofmannsthal, Max Reinhardt, Richard Strauss, Alfred Roller and Franz Schalk determined to establish the Salzburg Festival with a view to reconciling the peoples of war-torn Europe.

From its inception, the festival was conceived of as a project to combat existential crisis and the erosion of values in modern society as well as the identity crisis affecting not only individuals but also entire nations.

For a short period of five to six weeks in the summer, the Salzburg Festival stages operatic, theatrical and orchestral performances of outstanding artistic merit against a backdrop of flawlessly preserved Baroque architecture which is itself a marvel.

The Salzburg Festival rightly enjoys a reputation for being the world’s largest and most prestigious festival, and not only in terms of the sheer number of performances, annual visitors and tickets offered for sale. Anyone who is anyone in the performing arts - conductors, directors, singers, actors and virtuosos of international repute - sets aside July and August for the rendezvous by the Salzach.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...